PHARMACOECONOMIC ASSESSMENT OF THE AVAILABILITY OF MEDICINES FOR THE TREATMENT OF RESPIRATORY DISEASES
DOI:
https://doi.org/10.11603/2312-0967.2017.3.8114Keywords:
respiratory diseases, combination drug, extract, herbal raw materials, economic affordability, cost.Abstract
The aim of the work. Diseases of the respiratory system (DRS) remain one of the most common pathology in the structure of morbidity of population ofUkraine. The problem of increasing the efficiency and affordability of treatment of the DRS remains relevant. Thus, in conditions of limited health care resources, and low solvency of the population increasing socio-economic importance of pharmacoeconomic assessment of the availability of pharmaceutical drugs, to what this publication is devoted to.
Based on the above, the aim of the study was the analysis of the price indices of the availability of drugs for the treatment of the DRS, including new drugs proposed for implementation in production.
Materials and Methods. The analysis of the dynamics of price indices, the liquidity of the prices and availability of mucolytic and expectorant drugs using statistical methods took place. Implemented calculation of the forecast cost of new drugs. Information database: the compendium, price lists, data from the state statistics for 2012–2016.
Results and Discussion. In the first stage of research the analysis of price indicators availability of drugs of reference groups of developing combination drug «Bronkhosten» that includes a complex of extracts of herbal raw materials has been realized. The average wholesale prices expectorants and mucolytic drugs for 2013–2016 have been monitored. It has been concluded that overall liquidity indicators Сliq of the drugs of mucolityc and expectorant action for 2012–2016 does not exceed the maximum allowable values, that indicating a stable level of competition in the studied market segment. Indicators of availability of drugs of expectorant and mucolytic actions have been defined. The cost and selling price of the drug on the basis of material calculations of production has been calculated.
Conclusions. The analysis of indicators of price indices, liquidity ratios and affordability shows that now the market of drugs for the treatment of respiratory diseases characterized by a wide range of appropriate economic (price) availability of medicines.
The calculation of cost of proposed for implementation integrated herbal drug «Bronkhosten» has been made. According to the results of the calculations, the projected wholesale selling prices (including VAT 20 %) will be from 16.00 to 20.00 UAH for packaging. Comparative analysis of prices for the reference drugs allows making a conclusion about the economic feasibility of manufacturing the proposed drug.References
Available from: http://medstat.gov.ua/ukr/statreports.html.
Maiko, DV, & Kukhtenko OS. [Actuality of phytotherapy in diseases of the respiratory tract]. In: Suchasni dosiahnennia farmatsevtychnoi tekhnolohii ta botekhnolohii: mater. IV nauk.-prakt. konf. z mizhnar. uchastiu. Kharkіv: NUPh; 2014. Ukrainian.
Available from: http://compendium.com.ua/.
Nemchenko AS, Kosyachenko KL, Nemchenko OA. [Pricing for drugs: a monograph]. Kharkiv: Vy-vo FOP Vyrovets AP Vydavnycha hrupa «Apostrof»: 2012. 304. Ukrainian
Available from: http://www.ukrstat.gov.ua/.
Available from: http://zakon3.rada.gov.ua/laws/show/z0027-00/.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal .
- Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).